

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
02 February 2023 (02.02.2023)



(10) International Publication Number
WO 2023/009663 A1

(51) International Patent Classification:

A61K 31/44 (2006.01) A61K 31/427 (2006.01)
A01N 43/78 (2006.01) A61K 31/4409 (2006.01)
A61K 31/4164 (2006.01) C07D 213/16 (2006.01)
A61K 31/426 (2006.01)

(21) International Application Number:

PCT/US2022/038577

(22) International Filing Date:

27 July 2022 (27.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/226,557	28 July 2021 (28.07.2021)	US
63/305,103	31 January 2022 (31.01.2022)	US
63/368,034	08 July 2022 (08.07.2022)	US

(71) Applicant: **NURA BIO, INC.** [US/US]; 161 Oyster Point Blvd., Suite 200, South San Francisco, California 94088 (US).

(72) Inventors: **KOLLURI, Rao**; 161 Oyster Point Blvd., Suite 200, South San Francisco, California 94088 (US). **TEGLEY, Christopher Michael**; 161 Oyster Point Blvd., Suite 200, South San Francisco, California 94088 (US). **ZHU, Liusheng**; 161 Oyster Point Blvd., Suite 200, South San Francisco, California 94088 (US). **BROWN, Sean Pomeroy**; 161 Oyster Point Blvd., Suite 200, South San Francisco, California 94088 (US). **TASKER, Andrew Stewart**; 161 Oyster Point Blvd., Suite 200, South San Francisco, California 94088 (US). **GRICE, Cheryl A.**; 161 Oyster Point Blvd., Suite 200, South San Francisco, California 94088 (US). **REYNOLDS, Charles Howard**; 161 Oyster Point Blvd., Suite 200, South San Francisco, California 94088 (US).

(74) Agent: **MALECHA, Jim**; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS

(57) Abstract: This disclosure is drawn to pyridine derivatives, compositions thereof: and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological disorders. SARM1 activation can cause a rapid reduction in NAD⁺ levels in injured axons, which then undergo degeneration. In particular embodiments, the compounds inhibit axonal degeneration, including axonal degeneration that results from reduction or depletion of NAD⁺ (e.g., inhibition of SARM1 NADase).



WO 2023/009663 A1